419 related articles for article (PubMed ID: 35663281)
1. Immunotherapy in indolent Non-Hodgkin's Lymphoma.
Amhaz G; Bazarbachi A; El-Cheikh J
Leuk Res Rep; 2022; 17():100325. PubMed ID: 35663281
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
5. Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.
Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
Expert Opin Investig Drugs; 2015; 24(7):897-912. PubMed ID: 25900401
[TBL] [Abstract][Full Text] [Related]
6. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
7. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
8. Novel CD20 monoclonal antibodies for lymphoma therapy.
Cang S; Mukhi N; Wang K; Liu D
J Hematol Oncol; 2012 Oct; 5():64. PubMed ID: 23057966
[TBL] [Abstract][Full Text] [Related]
9. Role of antibody-based therapy in indolent non-Hodgkin's lymphoma.
Willard P; McKay J; Yazbeck V
Leuk Res Rep; 2021; 16():100275. PubMed ID: 34765437
[TBL] [Abstract][Full Text] [Related]
10. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
11. Antibody-based therapy of non-Hodgkin's lymphoma.
Foran JM
Best Pract Res Clin Haematol; 2002 Sep; 15(3):449-65. PubMed ID: 12468399
[TBL] [Abstract][Full Text] [Related]
12. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
Front Immunol; 2021; 12():681984. PubMed ID: 34248965
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.
Ollila TA; Olszewski AJ
Cancer Manag Res; 2021; 13():3935-3952. PubMed ID: 34017197
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
15. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies.
Qi J; Chen SS; Chiorazzi N; Rader C
Methods; 2019 Feb; 154():70-76. PubMed ID: 30145356
[TBL] [Abstract][Full Text] [Related]
16. Novel agents in indolent lymphomas.
Merli M; Ferrario A; Basilico C; Maffioli M; Caramazza D; Appio L; Arcaini L; Passamonti F
Ther Adv Hematol; 2013 Apr; 4(2):133-48. PubMed ID: 23610620
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
Leslie LA
Curr Treat Options Oncol; 2021 Oct; 22(12):111. PubMed ID: 34694508
[TBL] [Abstract][Full Text] [Related]
18. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
19. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]